Plaintiffs: Pfizer, Inc., Northwestern University,
Warner-Lambert Company LLC, PF Prism CV
Defendants: Wockhardt Limited, Wockhardt USA, LLC
Case Number: 1:13-cv-00143
Date Filed: January 25, 2013
Court: Delaware District Court
Patent-in-Suit: US6197819
The patent US6197819 involved in this suit is currently assigned[*] to Northwestern University (source: Maxval’s Assignment Database). The patent entitled Gamma Amino Butyric
Acid Analogs and Optical Isomers was issued on March 06, 2001 and expires[†]
on March 06, 2018. The patent describes compound of the formula ##STR1##
wherein R.sub.1 is a straight or branched alkyl group having from 1 to 6 carbon
atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R.sub.2 is
hydrogen or methyl; and R.sub.3 is hydrogen, methyl or carboxyl; which is
useful in the treatment of seizure disorders.
The
Parties:
Pfizer is a research-based, global biopharmaceutical
company. The company's diversified global healthcare portfolio includes human
and animal biologic and small molecule medicines and vaccines, as well as
nutritional products.
Northwestern
University (NU) is
a private research university.
Warner-Lambert
Company LLC operates in three segments: pharmaceutical products, consumer health
care products, and confectionery products. It operates as a subsidiary of
Pfizer Inc.
Wockhardt is a pharmaceutical and biotechnology company
engaged in the pharmaceutical business. The Company together with its
subsidiaries is engaged in the business of manufacture and marketing of
pharmaceutical products.
As
in complaint:
Defendant
with the Abbreviated New Drug Application (ANDA) No. 204258 seeks approval of
FDA to generic version of Pfizer’s pharmaceutical product Lyrica®, a pregabalin
oral solution containing 20 mg/ml of pregabalin, which is covered by the
patent-in-suit.
Pfizer
(PF Prism) is the current holder[‡] of the New Drug Application (NDA) no. 22488 for
Lyrica, (source: Patent Marker) (see Fig. 1) with active ingredient as
pregabalin that is approved by FDA
on January 04, 2010. Lyrica is used to treat fibromyalgia, diabetic nerve pain, spinal cord
injury nerve pain and pain after shingles. It is also indicated to treat
partial onset seizures in adults with epilepsy who take 1 or more drugs for
seizures.
Other Case(s) Filed:
Other Case(s) Filed:
Pfizer
has filed nearly 150 cases and a few are listed below:
Defendants
|
Case
Number
|
Date
Filed
|
Status
|
Roxane
Laboratories
|
07/03/2012
|
Closed
|
|
Mylan
Pharmaceuticals
|
06/26/2012
|
Closed
|
|
Sandoz
|
06/25/2012
|
Closed
|
|
Watson Laboratories
|
06/26/2012
|
Closed
|
|
Anchen
Pharmaceuticals
|
06/26/2012
|
Closed
|
|
Zydus
Pharmaceuticals
|
06/22/2012
|
Pending
|
|
Wockhardt
|
06/22/2012
|
Pending
|
Table information sourced from
Maxval’s Litigation
Database.
If you are interested in knowing about the
case(s) filed by Pfizer, please contact us.To
get alerts on cases filed, subscribe to our Litigation Alerts.
[*] MaxVal offers Patent Assignment Alert service where subscribers
receive email alerts when assignments relating to target applications, patents
or entities of interest are recorded.
[†] Expected expiration date. Patent Term
Estimator is a free web-based tool that automatically calculates patent terms and
expiration dates for U.S. utility patents.
[‡] Patent Marker provides an online
environment where patentees can virtually mark products and search products for
patent-related information.
No comments:
Post a Comment